Skip to Content
Søk Menu

ESMO | European Society for Medical Oncology

ESMO 2024

Hanna Dillekås

Ingen nye studier vil umiddelbart endre brystkreftbehandlingen i Norge, men flere har potensial på sikt

/ Hanna Dillekås
BrystkreftESMO24 Play the Video

ESMO Norsk Aften 2025

BestPractice Nordic og Medmeet er glade for å kunne invitere til Norsk Aften ESMO 2025 i Berlin. Norsk Aften vil være en faglig og sosial begivenhet, hvor vi inviterer spesialister som deltar på ESMO i Barcelona til å møtes, diskutere og perspektivere høydepunkter og nettverke. Programmet starter med en vitenskapelig oppsummering av nyheter og høydepunkter fra de fire største onkologiske sykdommene med diskusjon. Vi avslutter med en hyggelig middag.

Josep M Llovet

Perhaps a New Treatment Option for Patients with Intermediate Hepatocellular Carcinoma

/ Josep M. Llovet
ESMO24Leverkreft Play the Video

Oncology • Meet the experts

Få tilgang

Abstracts fra ESMO 2024

PD-1 Inhibitors Have Shown Remarkable Efficacy

  • / BestPractice Nordic

Gastrointestinal Cancer: 14 Years to Reach the Final Conclusion

/ Onkologi / BestPractice Nordic

Several Unsettled Questions About Breast Cancer Treatment

/ Onkologi / BestPractice Nordic

Continued Progress for the Treatment of Gynecological Cancer But No Game-Changer

/ Onkologi / BestPractice Nordic

New Treatment Possibilities Improve Future Outcomes of Lung Cancer

/ Onkologi / BestPractice Nordic

The Choice of Immunotherapy and PARP Inhibitor for Gynecological Cancer

/ Onkologi / BestPractice Nordic
Se oversigt

MEDtalks fra ESMO 2024

Gedske Daugaard

Enzalutamide plus Radium223 Treatment as First-Line for mCRPC in a Nordic Perspective

/ Gedske Daugaard
ESMO24Prostatakreft Play the Video
Silke Gillessen

PEACE-3 study: Enzalutamide and Ra-223 as First-Line Therapy for mCRPC

/ Silke Gillessen
ESMO24Prostatakreft Play the Video
Mansoor Raza Mirza

ESMO 2024: Hope and Disappointment for Ovarian Cancer Treatment

/ Mansoor Raza Mirza
ESMO24Gynekologisk kreft Play the Video
Marco Donia

Significant Updates on Neoadjuvant Treatments for Stage 3 Melanoma

/ Marco Donia
ESMO24ImmunterapiMelanom Play the Video
Andrea Botticelli

Efficacy and Safety of Targeted Therapy vs Standard of Care in Patients with Solid Tumors

/ Andrea Botticelli
ESMO24Immunterapi Play the Video

Urgent Need for More Knowledge About Quality of Life and Symptoms in Cancer Patients over 80 Years of Age

/ Elisabeth Grov Beisland
ESMO24 Play the Video

Androgen Receptor Pathway Inhibitors (ARPIs) Are Superior to Taxanes for Castrate-Resistant Metastatic Prostate Cancer

/ Henrik Grönberg
ESMO24Prostatakreft Play the Video
Ingrid Dyvik

The Role of ctDNA in Precision Oncology – New Data from the IMPRESS-Norway Study

/ Ingrid Dyvik
ESMO24 Play the Video
Jørgen Bjerggaard Jensen

ctDNA-Guided Immunotherapy Shows Promising Results to Reduce Overtreatment and Improve Outcomes for Patients with Bladder Cancer

/ Jørgen Bjerggaard Jensen
BlærekreftESMO24 Play the Video
Bjørn H. Grønberg

Høydepunkter fra ESMO 2024 om lungekreft

/ Bjørn Henning Grønberg
ESMO24Lungekreft Play the Video
Claus Andrup Kristensen

LBA35: Positive Efficacy for Eftilagimod plus Pembrolizumab in Patients with Head and Neck Squamous Cell Carcinoma

/ Claus Andrup Kristensen
ESMO24 Play the Video
Daniel Heinrich

Highlights from ESMO 2024: More Intelligent Choice of Treatment in the Future

/ Daniel Heinrich
BlærekreftESMO24NyrekreftProstatakreft Play the Video
Peter Schmid

Addition of Pembrolizumab to Standard Chemotherapy Patients with Early-Stage Triple-Negative Breast Cancer Has the Potential for a New Standard of Care

/ Peter Schmid
BrystkreftESMO24 Play the Video
Fred Saad

Darolutamide May Be an Effective Alternative Treatment Option for mHSPC

/ Fred Saad
ESMO24Prostatakreft Play the Video
Philippe Barthélémy

Updated Real-World Data Confirm the Effectiveness of Avelumab in First-Line Maintenance Treatment of Advanced Urothelial Carcinoma

/ Philippe Barthelemy
BlærekreftESMO24 Play the Video
Giuseppe Viale

Trastuzumab Deruxtecan May Become New Standard of Care After ≥1 Endocrine-Based Therapy for Patients with HER2-low and -ultralow, HR+ mBC

/ Giuseppe Viale
BrystkreftESMO24 Play the Video
Hildur Helgadottir

The Effect of Adjuvant Treatment on Overall Survival in Melanoma Stage III Patients

/ Hildur Helgadottir
ESMO24Melanom Play the Video
Nancy Lin

New Hope for Patients with Breast Cancer Including Patients with Brain Metastases

/ Nancy Lin
BrystkreftESMO24 Play the Video
Load more

ESMO 2023

Pembrolizumab + Chemotherapy: a New Standard of Carefor Triple-Negative Breast Cancer

/ Onkologi / Peter Schmid

Utvalgte ESMO 2023 Høydepunkter: Prostatakreft

/ Onkologi / Daniel Heinrich

ESMO 2023 Highlights: Practice-Changing Research in Gynecologic Cancers

/ Onkologi / Kristina Lindemann

Two New Potential Game-Changers in the Treatment of Gastroesophageal Cancer

/ Onkologi / Lene Bæksgaard

ESMO 2023: Dobling av overlevelsesraten ved innovativ behandling for metastatisk blærekreft

/ Onkologi / Daniel Heinrich

ESMO 2023 • Meet the experts

Få tilgang

KEYNOTE 522 viser forsat forbedret event-fri overlevelse for patienter med triple-negativ brystcancer

/ Ann Søegaard Knop
BrystkreftESMO23
Kristina Lindemann

Potential New Standard of Care for Locally Advanced Cervical Cancer

/ Kristina Lindemann
ESMO23Gynekologisk kreft Play the Video
Mansoor Raza Mirza

Optimizing PARP Inhibitor Therapy for Ovarian Cancer

/ Mansoor Raza Mirza
ESMO23Gynekologisk kreft Play the Video
Ellinor Haukland

Enabling Patient Empowerment Through Digital Monitoring

/ Ellinor Christin Haukland
ESMO23Pasientinvolvering Play the Video
Marco Donia

ESMO 2023 Highlights: Developments in Melanoma

/ Marco Donia
ESMO23Melanom Play the Video
Kristina Lindemann

Oppdatering fra ESMO 2023 med fokus på kreft i livmorhals-, livmor- og endometrie

/ Kristina Lindemann
ESMO23Gynekologisk kreft Play the Video
Jonathan Spicer

Perioperative Pembrolizumab Shows Significant OS in ResectableNon-Small-Cell Lung Cancer

/ Jonathan Spicer
ESMO23Lungekreft Play the Video
Henrik Grönberg

Prostate Cancer: Adaptive, Biomarker-Driven Platform Trial Shows That New Hormonal Agents Have Better Efficacy for mCRPC

/ Henrik Grönberg
ESMO23Prostatakreft Play the Video

Selected ESMO 2023 Highlights: Endometrial Cancer Treatment

/ Shannon Westin
ESMO23Gynekologisk kreft Play the Video
Mansoor Raza Mirza

New Treatment Possibilities for Patients with Recurrent or Primary Advanced Endometrial Cancer

/ Mansoor Raza Mirza
ESMO23Gynekologisk kreft Play the Video
Jaffer Ajani

Findings from the SPOTLIGHT Study Demonstrate the Power of the New Biomarker Claudin-18.2.

/ Jaffer Ajani
ESMO23Mage-tarmkreft Play the Video
Arlene Siefker-Radtke

Urothelial Cancer: One Step Forward to Understand How to Combine and Sequence Treatments Against Novel Targets

/ Arlene O. Siefker-Radtke
BlærekreftESMO23 Play the Video
Load more

MEDtalks fra ESMO 2022

Endocrine Response for Routine Decision-making on Chemotherapy use in HR+/HER2-N0-1 Early Breast Cancer

/ Onkologi / Nadia Harbeck

Current landscape in the immuno-oncology treatment of non-melanoma skin cancers

/ Dermatologi / Paolo Antonio Ascierto

Sexual health in long-term breast cancer survivors

/ Onkologi / Solveig Katrine Smedsland

ICON trial update: Ipi+Nivo combination with chemotherapy does not improve survival

/ Fastleger / Jon Amund Kyte

The clinical value of circulating tumor DNA in renal cancer

/ Onkologi / Lars Dyrskjøt Andersen

Outstanding results of ovarian cancer treatment

/ Onkologi / Clare Scott

Optimizing the front-line PARP-inhibitor treatment of ovarian cancer from a Nordic perspective

/ Onkologi / Kristina Lindemann

Efficacy of trastuzumab-deruxtecan therapy in HER2-positive breast cancer

/ Onkologi / Angelika Starzer

ESMO Highlights: Promising data for the frontline treatment of gynecologic cancer

/ Onkologi / Kristina Lindemann

ESMO Highlights: Increase awareness of supportive and palliative care for patients with cancer

/ Onkologi / Christina H. Ruhlmann

ESMO Highlights: Practical changes for treatment of lower gastrointestinal tumors

/ Onkologi / Marco Gerlinger

First-line atezolizumab treatment significantly improves overall survival in patients with NSCLC and not eligible for a platinum-containing regimen

/ Onkologi / Siow Ming Lee

Prostatakreft – høydepunkter fra ESMO 2022

/ Onkologi / Daniel Heinrich

COSMIC-313 – the first metastatic renal cell carcinoma (RCC) phase 3 trial with a doublet nivolumab plus ipilimumab

/ Onkologi / Toni K. Choueiri

Two years of ADT reduce the risk of metastases in patients undergoing post-prostatectomy radiotherapy

/ Onkologi / Chris Parker

Abstracts fra ESMO 2022

MCED blood test – a gamechanger for early cancer detection

/ BestPractice Nordic
ESMO22Kreft

Air pollution and lung cancer in never-smoking people 

/ BestPractice Nordic
ESMO22Lungekreft

Tumor-infiltrating lymphocytes improves PFS in metastatic melanoma

/ BestPractice Nordic
ESMO22Melanom

Combination of abemaciclib and trastuzumab +/- fulvestrant improved OS in women with HR+, HER2+ advanced breast cancer  

/ BestPractice Nordic
BrystkreftESMO22

A major threat to human health

/ BestPractice Nordic
ESMO22Kreft

PARP inhibitors are showing promising results in treating ovarian cancer 

/ BestPractice Nordic
ESMO22Gynekologisk kreft
Load more

Ten-Year Survival Data from a Groundbreaking Trial for the Treatment of Metastatic Melanoma

  • / BestPractice Nordic

Abstracts fra ESMO 2022

Doublet immune therapy for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy 

  • / BestPractice Nordic

ESMO 2022 –» Understanding the disease to provide better care for cancer patients»  

/ Onkologi / BestPractice Nordic
Se oversigt

ESMO 2021 • Highlights

Maintenance olaparib rechallenge in patients with ovarian carcinoma benefit outcomes

/ Eric Pujade-Lauraine
ESMO21Gynekologisk kreft Play the Video
Eric Pujade-Lauraine

PARP inhibitor olaparib shows significant improvement in PFS for patients with relapsed platinum-sensitive ovarian cancer

/ Eric Pujade-Lauraine
ESMO21Gynekologisk kreft Play the Video
Dana Chase

High-risk factors in patients with advanced ovarian cancer impact survival

/ Dana Chase
ESMO21Gynekologisk kreft Play the Video
Ma Pilar Barretina-Ginesta

First-line niraparib is associated with improvement in QA-PFS and QA-TWiST

/ Ma Pilar Barretina-Ginesta
ESMO21Gynekologisk kreft Play the Video
Roy S. Herbst

Clinical perspective of the COAST-study for unresectable Stage III NSCLC

/ Roy S. Herbst
ESMO21LungekreftNSCLC Play the Video
Roy S. Herbst

New combination with durvalumab improved ORR and PFS for unresectable Stage III NSCLC

/ Roy S. Herbst
ESMO21NSCLC Play the Video
Load more

ESMO 2021 • Highlights

Camillo Porta

New quality of life data with immune-based treatment of metastatic renal cell carcinoma

/ Camillo Porta
ESMO21Hudkreft Play the Video

Promising clinical results for heavily pretreated patients with colorectal cancer

/ Onkologi / Jared Weiss

Perspective of first line immune therapy of non-small-cell lung cancer

/ Onkologi / Ahmet Sezer

Osimertinib induction for patients with stage III metastatic EGFR NSCLC led to tumor shrinkage

/ Onkologi / Nir Peled

Potential as new standard treatment of HER2+ metastatic breast cancer

/ Onkologi / Javier Cortés

Nivolumab + chemo – a candidate for a new standard 1L treatment of advanced gastric/esophageal adenocarcinoma

/ Onkologi / Yelena Janjigian

Innhold fra ESMO 2020

Høydosert strålebehandling ved småcellet lungekreft i begrenset stadium

/ Bjørn Henning Grønberg
ESMO20Lungekreft

ESMO20: Update om lungecancer

/ Bjørn H. Grønberg
ESMO20Lungekreft Play the Video

ESMO20: Improved OS rate for metastatic, PD-L1-positive lung cancer patients

/ Julie Brahmer
ESMO20Lungekreft Play the Video

PIONeeR-studiet bringer os tættere på forståelsen af resistens mod PD-1/L1 inhibitorer

ESMO20Lungekreft

Lovende effekt på hjernemetastaser placerer osimertinib som adjuverende behandling af EGFR-positiv ikke-småcellet lungecancer

ESMO20Lungekreft

The AKT inhibitor ipatasertib in combination with abiraterone shows promising results in castration-resistant prostate cancer

BrystkreftESMO20

CDK 4/6-hæmmeren abemacitib i tidlig brystkræft har potentialet til at ændre praksis

BrystkreftESMO20

KEYNOTE 590 – Immunterapi kan blive ny førstelinjebehandling ved avanceret esophaguscancer

ESMO20Kreft
Mere

Back to top